The case for vitamin D supplementation in multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 2, Issue 4, 2013, Pages 281-306

  Ganesh, Aravind ^a   Apel, Sabrina ^b   Metz, Luanne ^a   Patten, Scott ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Causation; Dietary Supplements; Immunomodulation; Multiple Sclerosis; Relapse prevention; Vitamin D

Indexed keywords

ALFACALCIDOL; BETA INTERFERON; CALCITRIOL; CALCIUM; COLECALCIFEROL; CYTOKINE; ERGOCALCIFEROL; MAGNESIUM; METHYLPREDNISOLONE; PLACEBO; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; FLU LIKE SYNDROME; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; INFLAMMATION; LONGITUDINAL STUDY; LOW DRUG DOSE; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84880135135     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2012.12.008     Document Type: Review

References (92)

1. A. Achiron, Y. Barak, S. Miron, Y. Izhak, M. Faibel, and S. Edelstein Alfacalcidol treatment in multiple sclerosis Clinical Neuropharmacology 26 2 2003 53
2. Alikhani K, Kremenchutzky M. An observational long-term follow-up study of patients treated with high-dose oral calcitriol. In: Proceedings of the 25th congress of the European committee for the treatment and research in multiple sclerosis (ECTRIMS); 2009. Available from: http://registration.akm.ch/einsicht. php?XNABSTRACT-ID=95884&XNSPRACHE-ID=2&XNKONGRESS-ID= 106&XNMASKEN-ID=900.
3. L. Amezcua, R. Chung, D. Conti, and A. Langer-Gould Vitamin D levels in Hispanics with multiple sclerosis Neurology 2012 78(Meeting Abstracts 1):P05.105
4. A. Ascherio, K.L. Munger, and K.C. Simon Vitamin D and multiple sclerosis Lancet Neurology 9 6 2010 599 612
5. D.P. Auer, E.M. Schumann, T. Kumpfel, C. Gössl, and C. Trenkwalder Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis Annals of Neurology 47 2000 276 277
6. H. Bartosik-Psujek, J. Tabarkiewicz, K. Pocinska, Z. Stelmasiak, and J. Rolinski Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis Multiple Sclerosis 16 12 2010 1513 1516
7. B.D. Beretich, and T.M. Beretich Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis Multiple Sclerosis 15 8 2009 891 898
8. J.M. Bland, and D.G. Altman Statistics notes: Some examples of regression towards the mean British Medical Journal 309 1994 780
9. J.M. Burton, S. Kimball, R. Veith, A. Bar-Or, H.M. Dosch, and R. Cheung A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis Neurology 74 23 2010 1852 1859
10. Calabresi P, Ratchford J, Eckstein C, Saidha S, Harrison D, Newsome S. Johns Hopkins University. A pilot study to assess the relative safety and immunology effects of low dose versus high dose cholecalciferol supplementation in patients with multiple sclerosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Oct 31]. Available from: http://clinicaltrials.gov/show/NCT01024777 NLM Identifier: NCT01024777, in preparation
11. M.T. Cantorna, C.E. Hayes, and H.F. DeLuca 1,25-DihydroxyvitaminD3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis Proceedings of the National Academy of Sciences of the United States of America 93 1996 7861 7864
12. M.T. Cantorna, C. Munsick, C. Bemiss, and B.D. Mahon 1,25- Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental urine inflammatory bowel disease Journal of Nutrition 130 2000 2648 2652
13. M.T. Cantorna, and B.D. Mahon Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence Experimental Biology and Medicine 229 2004 1136 1142
14. J.H. Chang, H.R. Cha, D.S. Lee, K.Y. Seo, and M.N. Kweon 1,25-dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis PLoS ONE 9 2010 e12925
15. A. Compston, and A. Coles Multiple sclerosis Lancet 359 9313 2002 1221 1231
16. J. Correale, M.C. Yssraelit, and M.I. Gaitan Immunomodulatory effects of vitamin D in multiple sclerosis Brain 132 5 2009 1146 1160
17. J. Correale, M.C. Ysrraelit, and M.I. Gaitan Vitamin D-mediated immune regulation in multiple sclerosis Journal of the Neurological Sciences 311 1-2 2011 23 31
18. Deleglise ASJ, Camu W. Merck KGaA and Merck Serono SAS. A multicentre, randomized, double-blind, placebo-controlled study of the efficacy of supplementary treatment with cholecalciferol (vitamin D3) in patients with relapsing multiple sclerosis (RMS) treated with subcutaneous interferon beta-1a 44μg 3 times weekly. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Oct 31]. Available from: http://clinicaltrials.gov/ct2/show/study/NCT01198132 NLM Identifier: NCT01198132, in preparation.
19. Demirkaya S, Terzi M, Genc G, Hamamcioglu K, Odabasi Z. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. In: Proceedings of the 25th congress of the European committee for the treatment and research in multiple sclerosis (ECTRIMS); 2009. Available from: http://registration.akm.ch/einsicht.php?XNABSTRACT-ID=95884&XNSPRACHE- ID=2&XNKONGRESS-ID=106&XNMASKEN-ID=900.
20. G. Disanto, A.E. Handel, J.M. Morahan, G.C. Deluca, S.M. Kimball, and E. Hyponnen Vitamin D and multiple sclerosis hospital admissions in Scotland Quarterly Journal of Medicine 104 2011 1001 1003
21. J. Dorr, S. Ohlraun, H. Skarabis, and F. Paul Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial Trials [Electronic Resource] 13 2012 15
22. A.F. Embry, L.R. Snowdon, and R. Vieth Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis Annals of Neurology 48 2 2000 271 272
23. J.A. Freiman, T.C. Chalmers, H. Smith, and R.R. Kuebler The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial New England Journal of Medicine 299 13 1978 690 694
24. J.M. Gelfand, B.A.C. Cree, J. McElroy, J. Oksenberg, R. Green, and E.M. Mowry Vitamin D in African Americans with multiple sclerosis Neurology 76 21 2011 1824 1830
25. P. Goldberg, M.C. Fleming, and E.H. Picard Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D Medical Hypotheses 21 2 1986 193 200
26. W.B. Grant Hypothesis - ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers Photochemistry and Photobiology 84 2008 356 365
27. L. Grau-Lopez, M.L. Granada, D. Raich, M. Naranjo, F.E. Borras, and E.M. Martinez-Caceres Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients BMC Neurology 12 2012 103
28. S.M. Handel, G. Disanto, L. Jarvis, R. McLaughlin, A. Fries, and G.C. Ebers Seasonality of admissions with multiple sclerosis in Scotland European Journal of Neurology 18 8 2010 1109 1111
29. C.E. Hayes, and E. Donald Acheson A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10 Medical Hypotheses 71 1 2008 85 90
30. C.E. Hayes Vitamin D: a natural inhibitor of multiple sclerosis Proceedings of the Nutrition Society 59 2000 531 535
31. J.P.T. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, and A.D. Oxman The Cochrane Collaboration's tool for assessing risk of bias in randomised trials British Medical Journal 343 2011 d5928
32. A.B. Hill The environment and disease: association or causation? Proceedings of the Royal Society of Medicine 58 1965 295 300
33. G.S. Hiremath, D. Cettomai, M. Baynes, J.N. Ratchford, S. Newsome, and D. Harrison Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis Multiple Sclerosis 15 6 2009 735 740
34. P.M. Ho, P.N. Peterson, and F.A. Masoudi Evaluating the evidence: is there a rigid hierarchy? Circulation 118 2008 1675 1684
35. T. Holmoy, A. Lossius, T.A. Gundersen, S.M. Moen, M. Castellazzi, and E. Fairnardi Intrathecal levels of vitamin D and IgG in multiple sclerosis Acta Neurologica Scandinavica 125 6 2012 e28 e31
36. T. Holmoy, S.M. Moen, T.A. Gundersen, M.F. Holick, E. Fainardi, and M. Castellazzi 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis Multiple Sclerosis 15 11 2009 1280 1285
37. T. Holmoy Vitamin D status modulates the immune response to Epstein Barr virus: Synergistic effect of risk factors in multiple sclerosis Medical Hypotheses 70 1 2008 66 69
38. E. Hypponen, and C. Power Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors American Journal of Clinical Nutrition 85 2007 860 868
39. A.J. Idrovo Three criteria for ecological fallacy Environmental Health Perspectives 119 8 2011 a332
40. M.T. Kampman, L.H. Steffensen, S.I. Mellgren, and L. Jorgensen Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial Multiple Sclerosis 18 8 2012 1144 1151
41. K.S. Khan, E. Ball, C.E. Fox, and C. Meads Systematic reviews to evaluate causation: an overview of methods and application Evidence-Based Medicine 17 5 2012 137 141
42. S.M. Kimball, J.M. Burton, P.G. O'Connor, and R. Vieth Urinary calcium response to high dose vitamin D3 with calcium supplementation in patients with multiple sclerosis Clinical Biochemistry 44 10-11 2011 930 932
43. S.M. Kimball, M.R. Ursell, P. O'Connor, and R. Vieth Safety of vitamin D3 in adults with multiple sclerosis American Journal of Clinical Nutrition 86 3 2007 645 651
44. S.M. Kimball, R. Vieth, H.M. Dosch, A. Bar-Or, R. Cheung, and D. Gagne Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis Journal of Clinical Endocrinology and Metabolism 96 9 2011 2826 2834
45. S. Knippenberg, E. Peelen, J. Smolders, M. Thewissen, P. Menheere, and J.W. Cohen Tervaert Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission Journal of Neuroimmunology 239 1-2 2011 80 86
46. S. Knippenberg, J. Smolders, M. Thewissen, E. Peelen, J.W. Tervaert, and R. Hupperts Effect of vitamin D(3) supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis Multiple Sclerosis 17 12 2011 1418 1423
47. A. Langer-Gould, S. Huang, S.K. Van Den Eeden, R. Gupta, A.D. Leimpeter, and K.B. Albers Vitamin D, pregnancy, breastfeeding, and postpartum multiple sclerosis relapses Archives of Neurology 68 3 2011 310 313
48. K.I. Loken-Amsrud, T. Holmoy, S.J. Bakke, A.G. Beise, K.S. Bjerve, and B.T. Bjornara Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment Neurology 79 3 2012 267 273
49. R.M. Lucas, A.L. Ponsonby, K. Dear, P.C. Valery, M.P. Pender, and B.V. Taylor Sun exposure and vitamin D are independent risk factors for CNS demyelination Neurology 76 6 2011 540 548
50. A.P. Lysandropoulos, E. Jaquiery, S. Jilek, G. Pantaleo, M. Schluep, and R.A. Du Pasquier Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects Journal of Neuroimmunology 233 1-2 2011 240 244
51. B.D. Mahon, S.A. Gordon, J. Cruz, F. Cosman, and M.T. Cantorna Cytokine profile in patients with multiple sclerosis following vitamin D supplementation Journal of Neuroimmunology 134 1 2003 128 132
52. J.D. Maxwell Seasonal variation in vitamin D Proceedings of the Nutrition Society 54 1994 533 543
53. R. McCarney, J. Warner, S. Iliffe, R. van Haselen, M. Griffin, and P. Fisher The Hawthorne Effect: a randomised, controlled trial BMC Medical Research Methodology 7 2007 30
54. W.I. McDonald, A. Compston, G. Edan, D. Goodkin, H.P. Hartung, and F.D. Lublin Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis Annals of Neurology 50 2001 121 127
55. T.Y. McDowell, S. Amr, W.J. Culpepper, P. Langenberg, W. Royal, and C. Bever Sun exposure, vitamin D and age at disease onset in relapsing multiple sclerosis Neuroepidemiology 36 1 2011 39 45
56. Miller A, et al. Carmel Medical Center. A one year prospective, randomized, double blind interventional study to assess tolerability, quality of life and immunomodulation with interferon beta combined with vitamin D in patients with relapsing remitting multiple sclerosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Oct 31]. Available from: http://clinicaltrials.gov/ct2/show/NCT01005095 NLM Identifier: NCT01005095.
57. G. Mosayebi, A. Ghazavi, K. Ghasami, Y. Jand, and P. Kokhaei Therapeutic effect of vitamin D3 in multiple sclerosis patients Immunological Investigations 40 6 2011 627 639
58. E.M. Mowry, L.B. Krupp, M. Milazzo, D. Chabas, J.B. Strober, and A.L. Belman Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis Annals of Neurology 67 5 2010 618 624
59. E.M. Mowry, E. Waubant, C.E. McCulloch, D.T. Okuda, A.A. Evangelista, and R.R. Lincoln Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis Annals of Neurology 72 2012 234 240
60. Mowry EM, Waubant E. Johns Hopkins University, University of California San Francisco. Pharmacodynamic and immunologic effects of vitamin D supplementation in patients with multiple sclerosis and healthy controls. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Oct 31]. Available from: http://clinicaltrials.gov/ct2/show/ NCT01667796. NLM Identifier: NCT01667796, in preparation.
61. Mowry EM, Waubant E, Goodyear A, Cross A, Goodman A, Ontaneda D, et al. Johns Hopkins University. A randomized controlled trial of vitamin D supplementation in multiple sclerosis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Oct 31]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01490502. NLM Identifier: NCT01490502, in preparation.
62. K.L. Munger, L.I. Levin, B.W. Hollis, N.S. Howard, and A. Ascherio Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis Journal of the American Medical Association 296 23 2006 2832 2838
63. K.L. Munger, S.M. Zhang, E. O'Reilly, M.A. Hernán, M.J. Olek, and W.C. Willett Vitamin D intake and incidence of multiple sclerosis Neurology 62 2004 60 66
64. J.P. Neau, M.S. Artaud-Uriot, V. Lhomme, J.Y. Bounaud, F. Lebras, and L. Boissonnot Vitamine D et sclerose en plaques. Etude prospective d'une cohorte de patients de la region Poitou-Charentes Revue Neurologique 167 4 2011 317 323
65. S.M. Orton, L. Wald, C. Confavreux, S. Vukusic, J.P. Krohn, and S.V. Ramagopalan Association of UV radiation with multiple sclerosis prevalence and sex ratio in France Neurology 76 5 2011 425 431
66. H. Pakdaman, A.A. Harandi, K. Gharagozli, and S.K. Hosseini Association between serum 25(OH) Vitamin D3 concentrations and severity of disease in Iranian patients with multiple sclerosis Neurology 2012 78(Meeting Abstracts 1):P05.202
67. E. Peelen, J. Damoiseaux, J. Smolders, S. Knippenberg, P. Menheere, and J.W. Cohen Tervaert Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T-cell population during remission but not during relapse Journal of Neuroimmunology 240-241 2011 97 103
68. C. Pierrot-Deseilligny, S. Rivaud-Pechoux, P. Clerson, R. de Paz, and JC. Souberbielle Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation Therapeutic Advances in Neurological Disorder 5 4 2012 187 198
69. J. Rose, H. Seraj, D. Huseby, M. Rojas, H. Hill, and N. Carlson Gender based differences in clinical and MRI outcomes in multiple sclerosis with low vitamin D Neurology 2012 78(Meeting Abstracts 1):S50.004
70. W. Royal 3rd, Y. Mia, H. Li, and K. Naunton Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis Journal of Neuroimmunology 213 1-2 2009 135 141
71. T.F. Runia, W.C.J. Hop, Y.B. de Rijke, D. Buljevac, and R.Q. Hintzen Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis Neurology 79 2012 261 266
72. S.H. Scharla Prevalence of subclinical vitamin D deficiency in different European countries Osteoporosis International 8 1998 S7-12
73. T. Scott, D. Dworek, C. Hackett, and C. Schramke Vitamin D levels predict severity of MS and relapse activity Neurology 2012 78(Meeting Abstracts 1):P05.103
74. S. Shahbeigi, H. Pakdaman, S.M. Fereshtehnejad, G. Jalilzadeh, and M. Heydari Serum vitamin D3 concentration correlates with the severity of multiple sclerosis Neurology 2012 78(Meeting Abstracts 1):P05.101
75. V. Shaygannejad, M. Janghorbani, F. Ashtari, and H. Dehghan Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial Multiple Sclerosis International 2012 10.1155/2012/452541
76. S. Simpson Jr, B. Taylor, L. Blizzard, A.L. Ponsonby, F. Pittas, and H. Tremlett Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis Annals of Neurology 68 2 2010 193 203
77. J. Smolders, R. Hupperts, F. Barkhof, L.M. Grimaldi, T. Holmoy, and J. Killstein Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase II, multicenter, double -blind, randomized, placebo-controlled trial Journal of the Neurological Sciences 311 2011 44 49
78. J. Smolders, P. Menheere, A. Kessels, J. Damoiseaux, and R. Hupperts Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis Multiple Sclerosis 14 2008 1220 1224
79. J. Smolders, P. Menheere, M. Thewissen, E. Peelen, J.W.C. Tervaert, and R. Hupperts Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis Journal of Steroid Biochemistry and Molecular Biology 121 1-2 2010 243 246
80. J. Smolders, M. Thewissen, E. Peelen, P. Menheere, J.W.C. Tervaert, and J. Damoiseaux Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis PLoS ONE 4 8 2009 e6635
81. J. Smolders, E. Peelen, M. Thewissen, J.W. Cohen Tervaert, P. Menheere, and R. Hupperts Safety and T-cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis PLoS ONE 5 12 2010 e15235
82. M. Soilu-Hanninen, L. Airas, I. Mononen, A. Heikkila, M. Viljanen, and A. Hanninen 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis Multiple Sclerosis 11 3 2005 266 271
83. M. Soilu-Hanninen, J. Aivo, B.M. Lindstrom, I. Elovaara, M.L. Sumelahti, and M. Farkkila A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis Journal of Neurology, Neurosurgery, and Psychiatry 83 5 2012 565 571
84. M. Soilu-Hanninen, M. Laaksonen, I. Laitinen, J.P. Eralinna, E.W. Lilius, and I. Mononen A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis Journal of Neurology, Neurosurgery, and Psychiatry 79 2 2008 152 157
85. Steffensen L, Brustad M, Skeie G, Jorgensen L, Figenschau Y, Kampman M. Vitamin D status in individuals with multiple sclerosis at baseline and after supplementation with 20,000 IU cholecalciferol a week for 48 weeks. In: Proceedings of the 25th congress of the European committee for the treatment and research in multiple sclerosis (ECTRIMS); 2009. Available from: http://registration.akm.ch/einsicht.php?XNABSTRACT-ID=94079&XNSPRACHE-ID= 2&XNKONGRESS-ID=106&XNMASKEN-ID=900.
86. M.S. Stein, Y. Liu, O.M. Gray, J.E. Baker, S.C. Kolbe, and M.R. Ditchfield A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis Neurology 77 17 2011 1611 1618
87. N. Stewart, S. Simpson Jr, I. van der Mei, A.L. Ponsonby, L. Blizzard, and T. Dwyer Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS Neurology 79 3 2012 254 260
88. I.A.F. van der Mei, A.L. Ponsonby, T. Dwyer, L. Blizzard, B.V. Taylor, and T. Kilpatrick Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia Journal of Neurology 254 5 2007 581 590
89. M.H. Vogt, J. ten Kate, R.J. Drent, C.H. Polman, and R. Hupperts Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers Multiple Sclerosis 16 4 2010 443 449
90. S. Vojinovic, J. Vojinovic, V. Cosic, and V. Savic Effects of alfacalcidol therapy on serum cytokine levels in patients with multiple sclerosis [Serbian] Srpski Arhiv Za Celokupno Lekarstvo 133 2 2005 124 128
91. B. Weinstock-Guttman, R. Zivadinov, J. Qu, D. Cookfair, X. Duan, and E. Bang Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients Journal of Neurology, Neurosurgery, and Psychiatry 82 2 2011 189 195
92. D.M. Wingerchuk, J. Lesaux, G.P. Rice, M. Kremenchutzky, and G.C. Ebers A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis Journal of Neurology, Neurosurgery, and Psychiatry 76 9 2005 1294 1296